Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 515

1.

Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus.

Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR.

Antiviral Res. 2003 Mar;58(1):47-56.

PMID:
12719006
2.

In vitro evaluation of cyanovirin-N antiviral activity, by use of lentiviral vectors pseudotyped with filovirus envelope glycoproteins.

Barrientos LG, Lasala F, Otero JR, Sanchez A, Delgado R.

J Infect Dis. 2004 Apr 15;189(8):1440-3. Epub 2004 Apr 1.

PMID:
15073681
4.
6.

Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner.

Bolmstedt AJ, O'Keefe BR, Shenoy SR, McMahon JB, Boyd MR.

Mol Pharmacol. 2001 May;59(5):949-54.

7.
8.

Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans.

Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J.

J Biol Chem. 2006 Sep 1;281(35):25177-83. Epub 2006 Jun 29.

9.

Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development.

Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH 2nd, Buckheit RW Jr, Nara PL, Pannell LK, Sowder RC 2nd, Henderson LE.

Antimicrob Agents Chemother. 1997 Jul;41(7):1521-30.

10.

Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989-1990 U.S. epizootic.

Jahrling PB, Geisbert TW, Jaax NK, Hanes MA, Ksiazek TG, Peters CJ.

Arch Virol Suppl. 1996;11:115-34.

PMID:
8800793
11.

Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice.

Gibb TR, Bray M, Geisbert TW, Steele KE, Kell WM, Davis KJ, Jaax NK.

J Comp Pathol. 2001 Nov;125(4):233-42.

PMID:
11798240
12.

A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever.

Bray M, Davis K, Geisbert T, Schmaljohn C, Huggins J.

J Infect Dis. 1998 Sep;178(3):651-61. Erratum in: J Infect Dis 1998 Nov;178(5):1553.

PMID:
9728532
13.

Inactivation of Ebola virus with a surfactant nanoemulsion.

Chepurnov AA, Bakulina LF, Dadaeva AA, Ustinova EN, Chepurnova TS, Baker JR Jr.

Acta Trop. 2003 Aug;87(3):315-20.

PMID:
12875924
14.

Properties of cyanovirin-N (CV-N): inactivation of HIV-1 by sessile cyanovirin-N (sCV-N).

Gandhi MJ, Boyd MR, Yi L, Yang GG, Vyas GN.

Dev Biol (Basel). 2000;102:141-8. Review.

PMID:
10794101
15.

Cyanovirin-N potently inhibits human immunodeficiency virus type 1 infection in cellular and cervical explant models.

Buffa V, Stieh D, Mamhood N, Hu Q, Fletcher P, Shattock RJ.

J Gen Virol. 2009 Jan;90(Pt 1):234-43. doi: 10.1099/vir.0.004358-0.

PMID:
19088294
16.

Dissecting carbohydrate-Cyanovirin-N binding by structure-guided mutagenesis: functional implications for viral entry inhibition.

Barrientos LG, Matei E, Lasala F, Delgado R, Gronenborn AM.

Protein Eng Des Sel. 2006 Dec;19(12):525-35. Epub 2006 Sep 29.

PMID:
17012344
18.

Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.

Mori T, Shoemaker RH, McMahon JB, Gulakowski RJ, Gustafson KR, Boyd MR.

Biochem Biophys Res Commun. 1997 Oct 29;239(3):884-8.

PMID:
9367864
19.

The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding.

Mariner JM, McMahon JB, O'Keefe BR, Nagashima K, Boyd MR.

Biochem Biophys Res Commun. 1998 Jul 30;248(3):841-5.

PMID:
9704015
20.

The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus.

Garrison AR, Giomarelli BG, Lear-Rooney CM, Saucedo CJ, Yellayi S, Krumpe LR, Rose M, Paragas J, Bray M, Olinger GG Jr, McMahon JB, Huggins J, O'Keefe BR.

Antiviral Res. 2014 Dec;112:1-7. doi: 10.1016/j.antiviral.2014.09.012. Epub 2014 Oct 5.

Supplemental Content

Support Center